AI Article Synopsis
- RET fusions, found in about 1% of primary lung tumor patients, have not been studied in patient-derived lung cancer cell lines yet.
- The CCDC6-RET fusion was identified in the LC-2/ad lung adenocarcinoma cell line, displaying unique sensitivity to the RET inhibitor vandetanib among 39 other non-small lung cancer lines.
- The LC-2/ad cell line could serve as a valuable tool for researching the molecular functions of RET-fusion proteins and their responses to RET inhibitors.
Article Abstract
Rearranged during transfection (RET) fusions have been newly identified in approximately 1% of patients with primary lung tumors. However, patient-derived lung cancer cell lines harboring RET fusions have not yet been established or identified, and therefore, the effectiveness of an RET inhibitor on lung tumors with endogenous RET fusion has not yet been studied. In this study, we report identification of CCDC6-RET fusion in the human lung adenocarcinoma cell line LC-2/ad. LC-2/ad showed distinctive sensitivity to the RET inhibitor, vandetanib, among 39 non-small lung cancer cell lines. The xenograft tumor of LC-2/ad showed cribriform acinar structures, a morphologic feature of primary RET fusion-positive lung adenocarcinomas. LC-2/ad cells could provide useful resources to analyze molecular functions of RET-fusion protein and its response to RET inhibitors.
Download full-text PDF |
Source |
|---|---|
| http://dx.doi.org/10.1097/JTO.0b013e3182721ed1 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
Want AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!